The estimated Net Worth of John P Kelley is at least $167 Tausend dollars as of 13 January 2015. Mr. Kelley owns over 10,000 units of Acorda Therapeutics Inc stock worth over $6,600 and over the last 20 years he sold ACOR stock worth over $0. In addition, he makes $160,898 as Non-Executive Independent Chairman of the Board at Acorda Therapeutics Inc.
John has made over 5 trades of the Acorda Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of ACOR stock worth $254,500 on 13 January 2015.
The largest trade he's ever made was exercising 50,000 units of Acorda Therapeutics Inc stock on 3 January 2007 worth over $913,500. On average, John trades about 2,933 units every 98 days since 2004. As of 13 January 2015 he still owns at least 10,000 units of Acorda Therapeutics Inc stock.
You can see the complete history of Mr. Kelley stock trades at the bottom of the page.
John P. Kelley serves as Non-Executive Independent Chairman of the Board of the Company. From November 2013 to April 2017, Mr. Kelley was Chief Executive Officer of Tenax Therapeutics, Inc. (formerly named Oxygen Biotherapeutics, Inc.), a company that focuses on developing products for the critical care market, where he also served as a member of the board of directors. From 2011 to 2013, Mr. Kelley was President, Chief Executive Officer, and a director of Phyxius Pharma, Inc., a privately-held development stage pharmaceutical company co-founded by Mr. Kelley in 2011 focused on developing products for use in acute care settings. Mr. Kelley became Chief Executive Officer of Tenax Therapeutics when it acquired Phyxius Pharma in 2013. Previously, Mr. Kelley was the President and Chief Operating Officer of The Medicines Company, a pharmaceutical company providing acute care hospital products worldwide, from 2004 to 2009. He also served on The Medicines Company’s board of directors from 2005 to 2009. From 2000 to 2004, Mr. Kelley held a series of positions at Aventis, a global pharmaceutical company, including Senior Vice President, Global Marketing and Medical, where he was accountable for worldwide brand management. Prior to the formation of Aventis, he held a series of positions at Hoechst Marion Roussel, Inc., a life sciences firm focused on pharmaceuticals, including, from 1998 to 1999, Vice President, Commercial Director, U.S. and, from 1995 to 1998, Vice President of Marketing. Mr. Kelley received a B.A. from Wilkes University and an M.B.A. from Rockhurst University. Mr. Kelley’s extensive knowledge of the pharmaceutical industry as well as his operations and marketing experience make him well positioned to provide advice and guidance to the Company at this stage of its development. The Board has determined that Mr. Kelley qualifies as an audit committee financial expert. Based on his public company and broad corporate experience, Mr. Kelley serves as Chair of our Compensat
As the Non-Executive Independent Chairman of the Board of Acorda Therapeutics Inc, the total compensation of John Kelley at Acorda Therapeutics Inc is $160,898. There are 8 executives at Acorda Therapeutics Inc getting paid more, with Ron Cohen having the highest compensation of $2,039,560.
John Kelley is 66, he's been the Non-Executive Independent Chairman of the Board of Acorda Therapeutics Inc since 2019. There are 4 older and 11 younger executives at Acorda Therapeutics Inc. The oldest executive at Acorda Therapeutics Inc is Lorin Randall, 76, who is the Independent Director.
John's mailing address filed with the SEC is C/O ACORDA THERAPEUTICS, INC., 2 BLUE HILL PLAZA, 3RD FLOOR, PEARL RIVER, NY, 10965.
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith und Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include: